Table 3.

Summary of findings

Potent P2Y12 oral inhibitors versus clopidogrel in patients with atrial fibrillation undergoing percutaneous coronary intervention
Patients or population: Patients treated with oral anticoagulants for AF undergoing PCI Intervention: Potent P2Y12 oral inhibitors (i.e. ticagrelor or prasugrel) Comparison: Clopidogrel
Outcomes	Relative risk (95% CI)	Events in the potent P2Y12 arm (events/patients)	Events in the clopidogrel arm (events/patients)	No. of patients (no. of study)	Certainty of evidence
Major bleeding or clinically relevant non-major bleeding	1.30 (1.06–1.59)	185/843	1500/9214	10,057 (4)	Moderatea
MACE	1.02 (0.57–1.82)	82/732	671/7878	8610 (3)	Lowb

AF atrial fibrillation, CI confidence interval, MACE major adverse cardiovascular events, PCI percutaneous coronary intervention

^aInconsistency: wide CIs

^bInconsistency: wide CIs; imprecision: heterogeneity and small sample size